Page 68 - Read Online

Page 158 Bibi et al. J Transl Genet Genom 2024;8:119-161 https://dx.doi.org/10.20517/jtgg.2023.50

205. Jennbacken K, Tesan T, Wang W, Gustavsson H, Damber JE, Welén K. N-cadherin increases after androgen deprivation and is
associated with metastasis in prostate cancer. Endocr Relat Cancer 2010;17:469-79. DOI PubMed
206. Tandon M, Vemula SV, Mittal SK. Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther
Targets 2011;15:31-51. DOI PubMed PMC
207. Colapietro A, Gravina GL, Petragnano F, et al. Antitumorigenic effects of inhibiting ephrin receptor kinase signaling by GLPG1790
against colorectal cancer cell lines in vitro and in vivo. J Oncol 2020;2020:9342732. DOI PubMed PMC
208. Chang FL, Tsai KC, Lin TY, Chiang CW, Pan SL, Lee YC. Effectiveness of anti-erythropoietin producing hepatocellular receptor
Type-A2 antibody in pancreatic cancer treatment. Heliyon 2023;9:e21774. DOI PubMed PMC
209. Yamaguchi S, Tatsumi T, Takehara T, et al. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived
peptide-pulsed dendritic cell vaccines. Cancer 2007;110:1469-77. DOI
210. Peng L, Oganesyan V, Damschroder MM, Wu H, Dall’Acqua WF. Structural and functional characterization of an agonistic anti-
human EphA2 monoclonal antibody. J Mol Biol 2011;413:390-405. DOI PubMed
211. Lee JW, Stone RL, Lee SJ, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin
Cancer Res 2010;16:2562-70. DOI PubMed PMC
212. Smith HA, Cronk RJ, Lang JM, McNeel DG. Expression and immunotherapeutic targeting of the SSX family of cancer-testis
antigens in prostate cancer. Cancer Res 2011;71:6785-95. DOI PubMed
213. Hale R, Sandakly S, Shipley J, Walters Z. Epigenetic targets in synovial sarcoma: a mini-review. Front Oncol 2019;9:1078. DOI
PubMed PMC
214. Smith HA, McNeel DG. The SSX family of cancer-testis antigens as target proteins for tumor therapy. Clin Dev Immunol
2010;2010:150591. DOI PubMed PMC
215. Smith HA, McNeel DG. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. J
Immunother 2011;34:569-80. DOI PubMed PMC
216. Liao Y, Wu M, Jia Y, Mou R, Li X. EpCAM as a novel biomarker for survivals in prostate cancer patients. Front Cell Dev Biol
2022;10:843604. DOI PubMed PMC
217. Ni J, Cozzi P, Beretov J, et al. Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy/radiotherapy
response in vivo. BMC Cancer 2018;18:1092. DOI PubMed PMC
218. Rybalov M, Ananias HJ, Hoving HD, van der Poel HG, Rosati S, de Jong IJ. PSMA, EpCAM, VEGF and GRPR as imaging targets
in locally recurrent prostate cancer after radiotherapy. Int J Mol Sci 2014;15:6046-61. DOI PubMed PMC
219. Yan Y, Zhou B, Qian C, et al. RIPK2 stabilizes c-Myc and is an actionable target for inhibiting prostate cancer metastasis. bioRxiv
2020. DOI
220. Yan Y, Zhou B, Qian C, et al. Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate
cancer metastasis. Nat Commun 2022;13:669. DOI PubMed PMC
221. You J, Wang Y, Chen H, Jin F. RIPK2: a promising target for cancer treatment. Front Pharmacol 2023;14:1192970. DOI PubMed
PMC
222. Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug
Discov 2019;18:197-218. DOI PubMed
223. Karpf AR, Bai S, James SR, Mohler JL, Wilson EM. Increased expression of androgen receptor coregulator MAGE-11 in prostate
cancer by DNA hypomethylation and cyclic AMP. Mol Cancer Res 2009;7:523-35. DOI PubMed PMC
224. Bai S, Wilson EM. Epidermal-growth-factor-dependent phosphorylation and ubiquitinylation of MAGE-11 regulates its interaction
with the androgen receptor. Mol Cell Biol 2008;28:1947-63. DOI PubMed PMC
225. Su S, Parris AB, Grossman G, Mohler JL, Wang Z, Wilson EM. Up-regulation of follistatin-like 1 by the androgen receptor and
melanoma Antigen-A11 in prostate cancer. Prostate 2017;77:505-16. DOI PubMed
226. Bai S, He B, Wilson EM. Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the
interdomain interaction. Mol Cell Biol 2005;25:1238-57. DOI PubMed PMC
227. Weon JL, Potts PR. The MAGE protein family and cancer. Curr Opin Cell Biol 2015;37:1-8. DOI PubMed PMC
228. Gasser S, Lim LHK, Cheung FSG. The role of the tumour microenvironment in immunotherapy. Endocr Relat Cancer
2017;24:T283-95. DOI PubMed
229. Stultz J, Fong L. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer
Prostatic Dis 2021;24:697-717. DOI PubMed PMC
230. Wu Z, Chen H, Luo W, et al. The landscape of immune cells infiltrating in prostate cancer. Front Oncol 2020;10:517637. DOI
PubMed PMC
231. Di Mitri D, Mirenda M, Vasilevska J, et al. Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence
and tumor inhibition in advanced prostate cancer. Cell Rep 2019;28:2156-68.e5. DOI PubMed PMC
232. Ollivier L, Labbé M, Fradin D, Potiron V, Supiot S. Interaction between modern radiotherapy and immunotherapy for metastatic
prostate cancer. Front Oncol 2021;11:744679. DOI PubMed PMC
233. Hess KR, Varadhachary GR, Taylor SH, et al. Metastatic patterns in adenocarcinoma. Cancer 2006;106:1624-33. DOI
234. Xiang L, Gilkes DM. The contribution of the immune system in bone metastasis pathogenesis. Int J Mol Sci 2019;20:999. DOI
PubMed PMC
235. Kim SW, Kim JS, Papadopoulos J, et al. Consistent interactions between tumor cell IL-6 and macrophage TNF-α enhance the growth